Labcorp has shown robust performance with quarterly results beating estimates due to high demand for diagnostic tests. Several investment groups have expressed confidence by acquiring or increasing shares in
LH, such as
Sumitomo Mitsui Trust Group,
Alexander Randolph Advisory, and
Principal Financial Group. Labcorp recently raised their revenue guidance midpoint due to strong Q3 earnings, displaying possible long-term value. However, there were some EPS misses in 2024 Q3 and Q2. Labcorp was successful in acquiring select assets from Invitae and the diagnostics business of BioReference Health. The firm is also considering ramping up mpox testing capacity. Notably,
HSBC upgraded
Laboratory Co. of America's status to Buy. Despite recent successes, there has been selling of shares by certain individuals and entities, illustrating mixed market sentiments. Significant issuer activity includes the pricing of senior notes due 2030, 2032, and 2034. Labcorp provided key clinical contributions developing precision diagnostics for ovarian cancer and an Alzheimer's diagnosis advancement. Their acquisition pursuits include Sequenom, LipoScience, and Bode Technology, expanding their healthcare footprint.
Laboratory Corporation of America Holdings LH News Analytics from Thu, 25 Sep 2014 07:00:00 GMT to Sat, 16 Nov 2024 11:08:07 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 0
